Volume 71, Issue 2, Pages (February 2017)

Slides:



Advertisements
Similar presentations
Volume 60, Issue 4, Pages (October 2011)
Advertisements

Volume 69, Issue 5, Pages (May 2016)
European Urology Focus
Volume 71, Issue 2, Pages (February 2017)
The PSA Era is not Over for Prostate Cancer
Volume 65, Issue 6, Pages (June 2014)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi  European Urology 
Testosterone Therapy in Men With Prostate Cancer
David Lorente, Karim Fizazi, Christopher Sweeney, Johann S. de Bono 
Volume 70, Issue 6, Pages (December 2016)
Volume 69, Issue 5, Pages (May 2016)
Volume 68, Issue 6, Pages e129-e131 (December 2015)
Volume 70, Issue 6, Pages (December 2016)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 5, Pages (November 2014)
Volume 69, Issue 5, Pages (May 2016)
Volume 65, Issue 6, Pages (June 2014)
Volume 68, Issue 1, Pages (July 2015)
Prostate Cancer Epidemic in Sight?
Volume 52, Issue 4, Pages (October 2007)
Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration- resistant Prostate Cancer in the Era of Precision Oncology  Philipp.
Volume 70, Issue 5, Pages (November 2016)
Volume 71, Issue 2, Pages (February 2017)
Volume 72, Issue 5, Pages (November 2017)
Volume 63, Issue 1, Pages (January 2013)
Volume 68, Issue 4, Pages (October 2015)
Volume 66, Issue 2, Pages (August 2014)
Volume 74, Issue 1, Pages (July 2018)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
A Stepping Stone Toward Personalized Oncology: Genomic Analysis of Circulating Tumor Cells to Guide Management of Metastatic Castration-resistant Prostate.
Volume 65, Issue 1, Pages (January 2014)
Volume 73, Issue 2, Pages (February 2018)
Volume 71, Issue 1, Pages 1-3 (January 2017)
Volume 70, Issue 4, Pages (October 2016)
Volume 53, Issue 4, Pages (April 2008)
Prostate Cancer Detection: A View of the Future
Volume 70, Issue 5, Pages (November 2016)
Volume 66, Issue 5, Pages (November 2014)
Volume 70, Issue 5, Pages (November 2016)
Volume 69, Issue 6, Pages (June 2016)
Volume 73, Issue 6, Pages (June 2018)
Luis Martínez-Piñeiro  European Urology Supplements 
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 53, Issue 2, Pages (February 2008)
Volume 64, Issue 4, Pages (October 2013)
Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers  Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Leonard S. Marks, Jiaoti Huang  European Urology 
Volume 72, Issue 1, Pages (July 2017)
Volume 66, Issue 2, Pages (August 2014)
Volume 74, Issue 2, Pages (August 2018)
Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.
Volume 62, Issue 3, Pages (September 2012)
Volume 50, Issue 5, Pages (November 2006)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 53, Issue 1, Pages (January 2008)
Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi  European Urology 
Volume 70, Issue 6, Pages (December 2016)
Volume 74, Issue 3, Pages (September 2018)
Volume 71, Issue 4, Pages (April 2017)
European Urology is “Your” Journal
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration- resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary.
Volume 69, Issue 5, Pages (May 2016)
European Urology Oncology
Volume 53, Issue 2, Pages (February 2008)
Joaquim Bellmunt  European Urology Supplements 
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Presentation transcript:

Volume 71, Issue 2, Pages 168-171 (February 2017) Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer  Nicholas J. Vogelzang, Karim Fizazi, John M. Burke, Ronald De Wit, Joaquim Bellmunt, Thomas E. Hutson, Edward Crane, William R. Berry, Kevin Doner, John D. Hainsworth, Pawel J. Wiechno, Kejian Liu, Michelle F. Waldman, Anita Gandhi, Debora Barton, Ulf Jungnelius, Abderrahim Fandi, Cora N. Sternberg, Daniel P. Petrylak  European Urology  Volume 71, Issue 2, Pages 168-171 (February 2017) DOI: 10.1016/j.eururo.2016.07.051 Copyright © 2016 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier overall survival (OS) curves by baseline circulating tumor cell (CTC) count (≥5 cells/7.5ml blood vs <5 cells/7.5ml blood). NR=not reached. European Urology 2017 71, 168-171DOI: (10.1016/j.eururo.2016.07.051) Copyright © 2016 European Association of Urology Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.